Skip to main content

Advertisement

Table 3 Grade 3–4 treatment-related acute adverse events

From: Using neoadjuvant chemotherapy and replanning intensity-modulated radiotherapy for nasopharyngeal carcinoma with intracranial invasion to protect critical normal tissue

  During neoadjuvant chemotherapy During concurrent chemoradiation
Event Grade 3 Grade 4 Grade 3 Grade 4
Hematological     
 Leukopenia 15(46.8%) 3(9.3%) 7(21.8%) 1(3.1%)
 Neutropenia 6(18.7%) 18(56.2%) 2(6.2%) 4(12.5%)
 Neutropenia fever 3(9.3%) 0(0.0%) 0(0.0%) 0(0.0%)
 Thrombocytopenia 0(0.0%) 0(0.0%) 3(9.3%) 1(3.1%)
 Anemia 0(0.0%) 0(0.0%) 2(6.2%) 0(0.0%)
Non-hematological     
 Fatigue 4(12.5%) 0(0.0%) 4(12.5%) 0(0.0%)
 Nausea/vomiting 4(12.5%) 0(0.0%) 4(12.5%) 0(0.0%)
 Ototoxicity 0(0.0%) 0(0.0%) 0(0.0%) 0(0.0%)
 Diarrhea 0(0.0%) 0(0.0%) 0(0.0%) 0(0.0%)
 Liver dysfunction 0(0.0%) 0(0.0%) 0(0.0%) 0(0.0%)
 Kidney dysfunction 0(0.0%) 0(0.0%) 0(0.0%) 0(0.0%)
 Stomatitis 1(3.1%) 0(0.0%) 8(25%) 0(0.0%)
 Dermatitis - - 1(3.1%) 0(0.0%)
 Xerostomia - - 9(28.1%) 0(0.0%)